Ro-statin - Instructions For Use, Price, Reviews, Analogues, Capsules 10 Mg

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Ro-statin

Ro-statin: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Ro-statin

ATX code: C10AA07

Active ingredient: rosuvastatin (Rosuvastatin)

Manufacturer: Ozone LLC (Russia)

Description and photo update: 2019-10-07

Prices in pharmacies: from 389 rubles.

Buy

Ro-statin is a hypolipidemic agent belonging to the group of statins, an inhibitor of HMG-CoA reductase.

Release form and composition

Ro-statin is produced in the form of capsules: hard gelatinous, opaque; dosage 5 mg - size No. 2, lid and body are pale gray; dosage 10 mg - size No. 2, yellow lid with a pale beige tint, pale gray body; dosage 20 mg - size No. 2, the lid is pale yellow with a beige tint, the body is pale gray; dosage 40 mg - size No. 0, dark brown cap, brown body; the contents of the capsules are microgranular powder or a mixture of powder and granules of white with a yellow tinge or white, the contents can be compacted into capsule-shaped lumps, crumbling under light pressure (5, 6, 7 or 10 pcs. in a blister strip made of aluminum foil and polyvinyl chloride films; 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 pcs.in a can made of polyethylene terephthalate or polymer made of polypropylene; in a carton (pack) 1, 2, 3, 4, 5, 6, 9 or 10 packs or 1 can and instructions for the use of Ro-statin; the complete set of 2–3 carton packs in a group packing is possible).

1 capsule contains:

• active substance: rosuvastatin calcium - 5.21 / 10.42 / 20.83 / 41.66 mg, which is equivalent to the content of rosuvastatin - 5/10/20/40 mg;
• additional substances: microcrystalline cellulose, lactose monohydrate (milk sugar), croscarmellose sodium, colloidal silicon dioxide, povidone-K25, magnesium stearate;
• components of the capsule body: gelatin, titanium dioxide, iron dye black oxide; additionally for 40 mg - dyes iron oxide red and iron oxide yellow;
• components of the capsule cap: gelatin, titanium dioxide, black iron oxide dye (5/40 mg), yellow iron oxide dye (10/20/40 mg), red iron oxide dye (40 mg).

Pharmacological properties

Pharmacodynamics

Rosuvastatin belongs to selective and competitive inhibitors of hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), an enzyme responsible for the transformation of 3-hydroxy-3-methylglutaryl coenzyme A into mevalonate, which is a precursor of cholesterol. Rosuvastatin demonstrates its effect mainly in the liver, where cholesterol (Xc) production and low density lipoprotein (LDL) catabolism are carried out.

Rosuvastatin promotes an increase in the number of hepatic LDL receptors on the cell surface, increases the uptake and catabolism of LDL, and as a result, suppresses the production of very low density lipoproteins (VLDL), thereby reducing the total number of LDL and VLDL. Rosuvastatin provides a decrease in elevated levels of LDL cholesterol (LDL-C), triglycerides (TG), total cholesterol, and increases the level of high-density lipoprotein cholesterol (HDL-C). An inhibitor of HMG-CoA reductase also lowers the level of apolipoprotein B (ApoB), VLDL-C, non-HDL-C, TG-VLDL and increases the concentration of apolipoprotein AI (ApoA-I), reduces the ratio of total cholesterol / cholesterol-HDL and cholesterol / non-HDL cholesterol -HDL, Xc-LDL / Xc-HDL, and the ratio of ApoV / ApoA-1.

The hypolipidemic therapeutic effect is observed already after 1 week from the start of the course of treatment with Ro-statin, after 2 weeks of therapy it reaches 90% of the maximum possible. The full maximum effect from the use of the drug, as a rule, is recorded 4 weeks after the start of therapy and is further maintained with regular intake of rosuvastatin. It demonstrates a good treatment result in adult patients with hypercholesterolemia (HCS) with or without hypertriglyceridemia, and does not depend on the gender of patients, age or their race, including with familial hypercholesterolemia (FHC) and diabetes mellitus.

When treated with rosuvastatin at a dose of 10 mg, in 80% of patients with HCS type IIa and IIb according to the Fredrickson classification (the average baseline level of LDL-C is approximately 4.8 mmol / l), LDL-C reaches less than 3 mmol / l. In the presence of a heterozygous form of CGHS, the use of rosuvastatin at a dose of 20–80 mg provided a positive dynamics of lipid profile indices. After 12 weeks of taking and titrating the dose to 40 mg per day, a 53% decrease in the level of LDL-C was recorded. In patients with a homozygous form of FHC with regular use of rosuvastatin at a dose of 20 and 40 mg, the average decrease in the content of LDL-C was 22%.

When combined with fenofibrate, an additive effect is observed in relation to the level of TG, and with nicotinic acid, when taken in lipid-lowering daily doses above 1000 mg, in relation to the level of HDL-cholesterol.

Pharmacokinetics

The peak plasma concentration (C _max) of rosuvastatin in the blood is observed approximately 5 hours after oral administration of ro-statin. The absolute bioavailability is 20% on average. The metabolic transformation of the active substance for the most part takes place in the liver, which is the main site for the production of cholesterol and the conversion of cholesterol-LDL. The volume of distribution (V _d) of the agent is approximately 134 liters. About 90% of the active component binds to blood plasma proteins, mainly albumin.

Approximately 10% of the product is metabolized. Rosuvastatin is a weak non-core substrate for metabolism with the participation of isoenzymes of the cytochrome P ₄₅₀ system. The main isoenzyme involved in the metabolism of the substance is the isoenzyme CYP2C9, to a lesser extent, isoenzymes CYP2C19, CYP2D6 and CYP3A4 are also involved in this process.

The main established metabolites of rosuvastatin are lactone metabolites and N-dysmethyl metabolite. Lactone metabolites are classified as pharmacologically inactive, the activity of N-dismethyl is about 50% weaker than that demonstrated by the active substance. More than 90% of the activity to inhibit circulating HMG-CoA reductase falls on rosuvastatin, the rest - on its metabolites.

On average, 90% of the dose of the administered drug is excreted unchanged with feces (both absorbed and non-absorbed). The rest is excreted by the kidneys. T _1/2 (half-life) of rosuvastatin from plasma is approximately 19 hours and does not change with increasing dose. Average geometric plasma clearance ~ 50 l / h (with a coefficient of variation of 21.7%). Like other inhibitors of HMG-CoA reductase, a membrane cholesterol transporter is involved in the hepatic uptake of rosuvastatin, which plays an important role in the hepatic elimination of the drug.

Systemic exposure of the drug increases in proportion to the dose. With daily use, pharmacokinetic parameters remain unchanged.

Age and gender do not have a clinically significant effect on the pharmacokinetics of Ro-statin.

In persons of the Mongoloid race (Chinese, Japanese, Filipinos, Koreans and Vietnamese), according to pharmacokinetic studies, an average two-fold increase in C _max and the area under the pharmacokinetic curve (AUC) of rosuvastatin is recorded in comparison with Europeans. Indian patients showed a 1.3-fold increase in C _max and median AUC. The analysis of pharmacokinetics did not reveal clinically significant differences in the corresponding indicators between individuals of the Caucasian and Negroid races.

Indications for use

• homozygous form of FHC - as an adjunct to diet and other lipid-lowering therapies (including LDL apheresis) or if the effect of such treatment is insufficient;
• primary HCS according to Fredrickson's classification (type IIa, including the heterozygous form of CHC) or mixed HCS IIb type - as an addition to the diet, in the case when diet, exercise, weight loss and other non-drug methods of treatment are insufficient;
• hypertriglyceridemia (type IV according to Fredrickson's classification) - an addition to the diet;
• atherosclerosis, in order to slow the progression - an addition to the diet in the case when treatment is indicated to reduce the level of total cholesterol and LDL cholesterol;
• arterial revascularization, heart attack, stroke and other serious cardiovascular complications - for the purpose of primary prevention in adult patients without clinical signs of coronary heart disease (IHD), but with an aggravating risk of its development (age after 60 years for women and after 50 years for men, C-reactive protein concentration ≥ 2 mg / L, with at least one of the additional risk factors present, such as low HDL-C, arterial hypertension, family history of early onset of coronary artery disease, smoking).

Contraindications

Absolute for all dosages:

• active phase of liver disease, including a steady increase in the serum activity of transaminases and any increase in the activity of the latter in the serum, exceeding more than 3 times the upper limit of the norm (UHN);
• severe renal impairment, with creatinine clearance (CC) below 30 ml / min;
• rare genetic diseases: glucose-galactose malabsorption syndrome, hypolactasia or lactase deficiency (since the lipid-lowering agent contains lactose);
• children and adolescents under 18 years of age;
• pregnancy, lactation period;
• lack of effective methods of contraception in women of reproductive age;
• combination therapy with cyclosporine (with this combination, the AUC of rosuvastatin increases by about 7 times);
• myopathy, predisposition to the occurrence of myotoxic complications - for a dose of 5/10/20 mg;
• hypersensitivity to any of the constituents of Ro-statin.

Additional absolute contraindications for 40 mg capsules:

• the presence of risk factors for the occurrence of myopathy / rhabdomyolysis, in particular: hypothyroidism, renal failure of moderate severity (CC below 60 ml / min), personal / family history of muscle lesions, a history of myotoxicity against the background of the use of other HMG-CoA reductase inhibitors, or fibrates;
• conditions that can cause an increase in the plasma level of rosuvastatin;
• alcohol abuse;
• combined reception with fibrates;
• belonging to the Mongoloid race.

Relative for all dosages (Ro-statin capsules should be taken with extreme caution):

• sepsis;
• arterial hypotension;
• extensive surgical interventions, trauma;
• anamnestic data on liver disease;
• severe endocrine, metabolic, electrolyte disturbances, uncontrolled seizures;
• advanced age over 65;
• mild renal dysfunction (CC above 60 ml / min) - for 40 mg capsules.

Additional relative contraindications for Ro-statin 10 mg, 20 mg and 5 mg capsules:

• tendency to develop myopathy / rhabdomyolysis, namely the presence of factors such as hypothyroidism, renal failure; personal / family history of hereditary muscle lesions and a previous history of myotoxicity with the administration of other HMG-CoA reductase inhibitors or fibrates;
• conditions that can cause an increase in the plasma concentration of the drug in the blood;
• belonging to the Mongoloid race;
• excessive alcohol consumption;
• combined use with fibrates.

Ro-statin, instructions for use: method and dosage

Ro-statin capsules should be taken orally: swallowed whole without opening or chewing with water.

The drug can be taken at any time of the day, regardless of meal time. Before the start of the course of therapy and during its duration, it is required to adhere to a standard cholesterol-lowering diet. The dose of Ro-statin is selected by the physician individually, taking into account the goals of treatment and the therapeutic response, in accordance with the current recommendations for the target lipid concentration.

For patients who have not previously received the drug, as well as transferred from the use of other HMG-CoA reductase inhibitors, the recommended initial dose is 5 or 10 mg, taken 1 time per day. When setting the initial dose, it is necessary to take into account the individual level of Xc content and the potential risk of cardiovascular complications, as well as the likelihood of undesirable effects. If necessary, the dose of Ro-statin can be increased 4 weeks after the start of the course.

Since side effects can occur more often with the use of 40 mg capsules than with lower doses of Ro-statin, titration of the dose up to 40 mg after additional intake for 4 weeks of a dose of the drug that exceeds the recommended initial dose can be performed only in patients with severe HCS, in which the desired treatment result was not achieved when a dose of 20 mg was prescribed. Moreover, such patients usually have a significant risk of developing cardiovascular complications (especially in those with FHC). When using Ro-statin at a dose of 40 mg, you should be under the close supervision of a specialist.

Patients who have not previously consulted a doctor are not recommended to take Ro-statin at a dose of 40 mg. When the dose is increased or 2–4 weeks after the start of the course of treatment, it is required to monitor lipid metabolism parameters and, if necessary, adjust the dose.

Since an increase in the systemic concentration of the drug was observed in patients of the Mongoloid race, when Ro-statin is prescribed to this group of patients, its initial dose should be 5 mg.

If there is a predisposition to myopathy, the recommended starting dose is also 5 mg.

Ro-statin 40 mg is contraindicated in patients of Asian origin and patients with a tendency to develop myopathy.

In carriers of genotypes ABCG2 (BCRP) c.421AA and SLCO1B1 (OATP1B1) c.521CC, an increase in AUC to rosuvastatin was observed when compared with carriers of genotypes ABCG2 c.421CC and SLCO1B1 c.521TT. The maximum dose of Ro-statin for patients with c.421AA or c.521CC genotypes should not exceed 20 mg once a day.

Side effects

Adverse reactions observed while taking Ro-statin are usually mild and go away on their own. The frequency of development of these phenomena is dose-dependent:

• central nervous system (CNS): often - dizziness, headache;
• musculoskeletal system: often - myalgia; rarely - myopathy (including myositis), rhabdomyolysis (with or without acute renal failure); increased activity of creatine phosphokinase (CPK), usually insignificant, asymptomatic and temporary; with an increase in CPK more than 5 times when compared with VGN, therapy is suspended;
• endocrine system: often - type 2 diabetes mellitus;
• digestive tract: often - abdominal pain, constipation, nausea; rarely - pancreatitis;
• urinary system: tubular proteinuria, when taking 10 and 20 mg - in less than 1% of patients, when taking 40 mg - in about 3%; when taking 20 mg, a slight change in the protein content in the urine is recorded; in general, proteinuria decreased / disappeared during therapy and was not associated with the occurrence of acute or progressive kidney damage;
• skin: infrequently - rash, skin itching, urticaria;
• hepatobiliary system: in a small number of patients - a reversible transient dose-dependent increase in the activity of hepatic transaminases;
• allergic reactions: rarely - hypersensitivity reactions, including angioedema;
• laboratory parameters: an increase in the concentration of bilirubin, glucose, the activity of gamma-glutamyl transpeptidase (GGTP), alkaline phosphatase; dysfunction of the thyroid gland;
• other reactions: often - asthenic syndrome.

Violations recorded during post-marketing use of Ro-statin:

• CNS: extremely rare - polyneuropathy, memory loss;
• hematopoietic system: rarely - thrombocytopenia;
• musculoskeletal system: extremely rare - arthralgia; with an unknown frequency - immuno-mediated necrotizing myopathy (IONM);
• digestive tract: rarely - increased activity of hepatic transaminases; extremely rare - hepatitis, jaundice; with an unknown frequency - diarrhea;
• urinary system: extremely rare - hematuria;
• respiratory system: with an unknown frequency - shortness of breath, cough;
• reproductive system: with an unknown frequency - gynecomastia;
• skin and subcutaneous fat: with an unknown frequency - Stevens-Johnson syndrome;
• others: with an unknown frequency - peripheral edema.

With the use of some statins, the following side effects have been observed: sleep disturbances (including insomnia and nightmares), depression, sexual dysfunction; in isolated cases - interstitial lung disease (ILD), especially with long-term drug treatment (symptoms of this complication may include unproductive cough, shortness of breath, deterioration in general well-being, weight loss, weakness, fever). If you suspect the development of IDL, statin therapy should be discontinued.

Overdose

With the simultaneous administration of several daily doses, the pharmacokinetic parameters of rosuvastatin do not change. In case of an overdose of Ro-statin, it is recommended to carry out symptomatic treatment and measures aimed at maintaining the activity of vital organs; there is no specific therapy for this condition. Monitoring of liver function and CPK levels is required. Hemodialysis is presumably ineffective.

special instructions

It is not recommended to determine the activity of CPK after intense physical exertion or with other available factors that can cause an increase in the activity of this enzyme, since they can complicate the interpretation of the results. If the initial level of CPK activity is significantly increased - 5 times higher than VGN, it is required to re-analyze after 5-7 days. It is not necessary to start therapy when the results of the repeated test confirm the initial CPK activity (more than 5 times higher than the ULN).

Before starting treatment with ro-statin in patients with a tendency to myopathy / rhabdomyolysis, it is necessary to carefully assess the ratio of the potential risk and the expected benefit from taking the drug and establish clinical observation for them.

If muscle pain / weakness or spasms occur unexpectedly during therapy, especially when accompanied by malaise and fever, you should immediately consult a doctor. Such patients urgently need to establish the activity of CPK, and in case of exceeding the last VGN by more than 5 times, suspend therapy. If muscle symptoms are severe and cause daily discomfort, even in the absence of a five-fold increase in CPK VGN levels, the drug should be discontinued. After resolution of symptoms and normalization of CPK activity, Ro-statin can be re-prescribed at a lower dose and with close monitoring. In the absence of symptoms, the appointment of routine monitoring of CPK activity is inappropriate.

During the period of therapy or after its completion, cases of IONM development were extremely rare, the clinical manifestations of which were persistent weakness of the proximal muscles and an increase in serum CPK activity. If this complication is suspected, additional studies of the muscular system, serological studies, and, if necessary, also immunosuppressive drugs may be prescribed.

In patients with HCS caused by hypothyroidism or nephrotic syndrome, treatment of the underlying diseases should be carried out before starting therapy with Ro-statin.

In individuals with glucose levels ranging from 5.6 to 6.9 mmol / L, taking rosuvastatin was associated with an increased risk of type 2 diabetes. Ro-statin, like other HMG-CoA reductase inhibitors, can increase the concentration of glucose in the blood.

Influence on the ability to drive vehicles and complex mechanisms

The effect of rosuvastatin on the ability to drive a car and other moving, potentially dangerous and complex mechanisms has not been studied. However, since dizziness may occur during the period of taking Ro-statin, caution is required when performing types of work that require increased concentration of attention and speed of psychomotor reactions.

Application during pregnancy and lactation

Ro-statin therapy is contraindicated during pregnancy and breastfeeding.

Against the background of treatment, women of childbearing age need to use reliable contraception. Due to the fact that cholesterol and other products of its biosynthesis are of great importance for the development of the fetus, the possible risk of suppression of HMG-CoA reductase outweighs the benefits of treatment with the drug in pregnant women. If pregnancy was diagnosed during therapy, Ro-statin must be canceled immediately.

There is no information on the excretion of the drug with breast milk, as a result of which, during lactation, its intake must be discontinued.

Pediatric use

There is no data confirming the safety and efficacy of drug treatment for children and adolescents. The experience of using the product in pediatric practice is limited. Taking Ro-statin is contraindicated in patients under 18 years of age.

With impaired renal function

Against the background of mild to moderate renal failure, the plasma level of rosuvastatin or N-dismethyl metabolite does not change significantly. It was found that in patients with severe renal failure (CC below 30 ml / min), the plasma level of rosuvastatin and N-dysmethyl metabolite in the blood is 3 and 9 times higher, respectively, than in healthy volunteers. In patients on hemodialysis treatment, the plasma content of the drug was approximately 50% higher than in healthy volunteers.

The use of Ro-statin in all dosages is contraindicated in severe renal failure (CC below 30 ml / min). Patients with moderate renal impairment (CC below 60 ml / min) are contraindicated to take 40 mg capsules, the recommended initial dose of the drug in such patients is 5 mg.

Patients receiving ro-statin at a dose of 40 mg should be monitored for renal function during treatment.

For violations of liver function

With varying degrees of impairment of hepatic function, an increase in T _{1/2 of} rosuvastatin was not recorded in patients with a score of 7 and below on the Child - Pugh scale, however, an increase in T _1/2 was revealed at least 2 times in two patients, whose condition was estimated at 8 and 9 points on the Child-Pugh scale. In patients with a score exceeding 9 on the Child-Pugh scale, there is no experience with the use of rosuvastatin.

In the presence of liver disease in the active phase, including a persistent increase in the serum activity of transaminases and any increase in the activity of the latter in the serum, exceeding the ULN by more than 3 times, the use of ro-statin is contraindicated. Before the start of the course and 3 months after the start of treatment, it is recommended to monitor liver function indicators.

Use in the elderly

Ro-statin should be used with caution in persons over 65 years of age. In patients over 70 years of age, the initial dose of rosuvastatin should not exceed 5 mg.

Drug interactions

• drugs related to inhibitors of transport proteins (in particular BCRP and OATP1B1): an increase in the level of rosuvastatin in plasma and an aggravation of the threat of the appearance of myopathy is possible, since rosuvastatin is able to bind to proteins of the OATP1B1 and BCRP transporters;
• lipid-lowering agents (including gemfibrozil, fibrates, nicotinic acid in lipid-lowering doses): an increase in AUC and plasma C _{max of} rosuvastatin in the blood was recorded when it was combined with gemfibrozil; a pharmacokinetically significant interaction of rosuvastatin with fenofibrate is not expected, however, there is a possibility of pharmacodynamic interaction; with the simultaneous use of these drugs with HMG-CoA reductase inhibitors, the threat of myopathy is aggravated, probably due to the ability of these substances to cause the development of myopathy when administered in monotherapy; the initial dose of rosuvastatin when used simultaneously with nicotinic acid (1000 or more mg per day), fibrates, gemfibrozil should be 5 mg; taking the drug at a dose of 40 mg with fibrates is contraindicated;
• human immunodeficiency virus (HIV) protease inhibitors, including combinations such as atazanavir / ritonavir, darunavir / ritonavir, tipranavir / ritonavir and others: the exact mechanism of this interaction has not been studied, but it was found that the combined use of rosuvastatin with these substances caused a significant increase in its exposure and an increase in the number of cases of myopathy and myositis in patients; these combinations are contraindicated;
• indirect anticoagulants (including warfarin): an increase in the international normalized ratio (INR) (prothrombin time) is possible at the beginning of the course of treatment with ro-statin or against the background of an increase in its dose, and with a decrease in dose or completion of therapy, a decrease in INR; when adjusting doses of rosuvastatin, as well as at the beginning and at the end of its course of administration, it is necessary to monitor INR;
• ezetimibe (at a dose of 10 mg): there was an increase in the AUC of rosuvastatin when combined with this drug in patients with HCS; the threat of the occurrence of adverse reactions due to pharmacodynamic interaction between these substances may increase;
• erythromycin: with the combined use of C _{max of} rosuvastatin decreased by 30%, and AUC - by 20%, these phenomena may be due to increased intestinal motility associated with the use of erythromycin;
• antacids containing aluminum and magnesium hydroxide: when a suspension of these agents is combined with rosuvastatin, a decrease in the concentration of the latter in plasma by approximately 50% was noted; this effect was less pronounced when antacids were taken 2 hours after using rosuvastatin; the significance of this interaction has not been studied;
• oral contraceptives / hormone replacement therapy: when rosuvastatin is combined with oral contraceptives, ethinyl estradiol AUC increased by 26%, and norgestrel AUC increased by 34%, these effects must be taken into account when determining the doses of oral contraceptives; similar changes cannot be excluded with the simultaneous administration of hormone replacement therapy and the use of ro-statin, since there are no pharmacokinetic data on their combined use; this combination, however, was widely used in clinical trials and was well tolerated;
• fluconazole (inhibitor of CYP2C9 and CYP3A4 isoenzymes), ketoconazole (inhibitor of CYP2A6 and CYP3A4 isoenzymes): no significant interaction of rosuvastatin with these substances was detected;
• isozymes of cytochrome P ₄₅₀: the interaction of ro-statin with other drugs at the metabolic level with the participation of these isoenzymes is not expected, since rosuvastatin does not belong to either inhibitors or inductors of cytochrome P ₄₅₀ isoenzymes and is a non-core substrate for them.

Analogs

Ro-statin analogues are Rosulip, Rosuvastatin-SZ, Rosucard, Krestor, Reddistatin, Suvardio, Roxera, Rosuvastatin-Vial, Akorta, Rosufast, etc.

Terms and conditions of storage

Store out of the reach of children, protected from light penetration, at a temperature not exceeding 25 ° C.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews of Ro-statin

According to reviews of Ro-statin found on medical websites and specialized forums, the drug quickly and effectively normalizes cholesterol levels and helps in the fight against atherosclerotic plaques. Patients note that a positive result of therapy is observed after regular intake of Ro-statin for 1 month in combination with a correct and balanced diet recommended by the attending physician. The advantages of a lipid-lowering agent also include its availability and convenient dosing regimen.

The disadvantages of this drug, many consider the presence of a large number of contraindications and adverse reactions.

Ro-statin price in pharmacies

For a package containing 30 capsules, the price of Ro-statin 10 mg can be 1200 rubles, 5 mg - 900 rubles.

Ro-statin: prices in online pharmacies

Drug name Price Pharmacy

Ro-statin 10 mg capsules 30 pcs. 389 r Buy

Ro-statin 5 mg capsules combination pack 1 + 1 30 pcs. 415 RUB Buy

Ro-statin 5 mg capsules 30 pcs. 439 r Buy

Ro-statin 20 mg capsule 30 pcs. 449 r Buy

Ro-statin capsules 10mg 30 pcs. (combi packing 1 + 1) RUB 538 Buy

Ro-statin 10 mg capsules combination pack 1 + 1 30 pcs. RUB 550 Buy

Ro-statin capsules 20mg 30 pcs. RUB 680 Buy

Ro-statin 20 mg capsules combination pack 1 + 1 30 pcs. 695 RUB Buy

See all offers from pharmacies

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!